Global Muscle Relaxant Drugs Market 2017-2021

  • ID: 4143906
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
until May 31st 2018
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Acorda Therapeutics
  • Canbex Therapeutics
  • Endo International
  • INSYS Therapeutics
  • Lannett Company
  • Novartis
  • MORE
About Muscle Relaxant Drugs

Muscle spasticity is caused by damage to the spinal cord or brain. Nerves in the brain and spinal cord help relax the muscles during the idle state. Conditions that affect the brain or spinal cord such as multiple sclerosis, cerebral palsy, and stroke can interfere with normal muscle relaxation, leading to involuntary muscle spasms. This will impair the ability to walk, work, sleep, or just function normally. The muscles can also become excessively tense and develop overactive or overresponsive reflexes. Severe cases can lead to deep disability, including an inability to straighten out joints.

The analysts forecast the global muscle relaxant drugs market to grow at a CAGR of 5.64% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global muscle relaxant drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Muscle Relaxant Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Pfizer
- Ipsen Group
- Allergan
- Novartis
- Teva Pharmaceuticals

Other prominent vendors
- Acorda Therapeutics
- Aldeyra Therapeutics
- Canbex Therapeutics
- Daewoong
- Emcure Pharmaceuticals
- Endo International
- Fresenius Kabi
- Galderma
- INSYS Therapeutics
- Johnson & Johnson
- Lannett Company
- Merz Pharma
- Mylan
- Par Pharmaceutical
- PhytoTech Therapeutics
- Revance Therapeutics
- Sun Pharmaceutical Industries
- Takeda Pharmaceutical

Market drivers
- Presence of a large patient pool driving adoption rates.
- For a full, detailed list, view the full report

Market challenges
- Side effects associated with use of muscle relaxants hamper adoption rates.
- For a full, detailed list, view the full report

Market trends
- Advanced drug delivery technologies fuels adoption of muscle relaxants.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acorda Therapeutics
  • Canbex Therapeutics
  • Endo International
  • INSYS Therapeutics
  • Lannett Company
  • Novartis
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of muscle spasticity and spasms

PART 06: Pipeline landscape

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by product category
  • Skeletal muscle relaxant drugs
  • Facial muscle relaxant drugs
PART 09: Geographical segmentation
  • Muscle relaxant drugs market in Americas
  • Muscle relaxant drugs market in EMEA
  • Muscle relaxant drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 12: Market trends
  • Anti-aging treatments driving adoption of facial relaxants
  • Advanced drug delivery technologies fuels adoption of muscle relaxants
  • Growing use of muscle relaxants in new indications and applications
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Pfizer
  • Allergan
  • Ipsen Group
  • Teva Pharmaceuticals
  • Novartis
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Key muscle relaxants
Exhibit 02: Pipeline landscape
Exhibit 03: Global muscle relaxant drugs market snapshot
Exhibit 04: Global muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global muscle relaxant drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Global muscle relaxant drugs market by product category 2016
Exhibit 08: Global skeletal muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 09: Global facial muscle relaxant drugs market 2016-2021 ($ millions)
Exhibit 10: Global muscle relaxant drugs market by geography 2016 and 2021
Exhibit 11: Global muscle relaxant drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 12: Market scenario in Americas
Exhibit 13: Muscle relaxant drugs market in Americas 2016-2021 ($ millions)
Exhibit 14: Market scenario in EMEA
Exhibit 15: Muscle relaxant drugs market in EMEA 2016-2021 ($ millions)
Exhibit 16: Market scenario in APAC
Exhibit 17: Muscle relaxant drugs market in APAC 2016-2021 ($ millions)
Exhibit 18: Key approvals for new indications
Exhibit 19: Key factors driving the market growth
Exhibit 20: Impact of drivers
Exhibit 21: Impact of challenges
Exhibit 22: Competitive structure analysis of global muscle relaxant drugs market 2016
Exhibit 23: Competitive analysis of global muscle relaxant drugs market
Exhibit 24: Strategic success factors of companies in global muscle relaxant drugs market
Exhibit 25: Pfizer: Strength assessment
Exhibit 26: Pfizer: Strategy assessment
Exhibit 27: Pfizer: Opportunity assessment
Exhibit 28: Allergan: Key highlights
Exhibit 29: Allergan: Strength assessment
Exhibit 30: Allergan: Strategy assessment
Exhibit 31: Allergan: Opportunity assessment
Exhibit 32: Ipsen Group: Key highlights
Exhibit 33: Ipsen Group: Strength assessment
Exhibit 34: Ipsen Group: Strategy assessment
Exhibit 35: Ipsen Group: Opportunity assessment
Exhibit 36: Teva Pharmaceuticals: Strength assessment
Exhibit 37: Teva Pharmaceuticals: Strategy assessment
Exhibit 38: Teva Pharmaceuticals: Opportunity assessment
Exhibit 39: Novartis: Strength assessment
Exhibit 40: Novartis: Strategy assessment
Exhibit 41: Novartis: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acorda Therapeutics
  • Canbex Therapeutics
  • Endo International
  • INSYS Therapeutics
  • Lannett Company
  • Novartis
  • MORE
New Report Released: – Global Muscle Relaxant Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global muscle relaxant drugs market: Pfizer, Ipsen Group, Allergan, Novartis, and Teva Pharmaceuticals.

Other Prominent Vendors in the market are: Acorda Therapeutics, Aldeyra Therapeutics, Canbex Therapeutics, Daewoong, Emcure Pharmaceuticals, Endo International, Fresenius Kabi, Galderma, INSYS Therapeutics, Johnson & Johnson, Lannett Company, Merz Pharma, Mylan, Par Pharmaceutical, PhytoTech Therapeutics, Revance Therapeutics, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.

Commenting on the report, an analyst from the research team said: “One trend in market is anti-aging treatments driving adoption of facial relaxants. The demand for anti-aging treatments is expected to drive the market growth. The increasing adoption of such treatments is due to the growing older population as baby boomers drive the demand. These individuals are more focused on drugs that target specific problems caused by aging such as wrinkles, which require facial muscle relaxants for the treatment. Wrinkles occur due to the stiffness in muscles. Consumers, especially the older population, are looking for products to maintain and improve their appearance. Currently, out of the total population in the world, those aged above 65 years form the fastest-growing population group, accounting for 8.1% of the total population in 2014. This share is expected to reach 16% by 2050. The rise in the aging population is expected to drive the demand for facial muscle relaxants. Furthermore, younger individuals are making changes in their lifestyles to maintain youthful-looking skin. This scenario is likely to change the market dynamics in the future.”

According to the report, one driver in market is expanding label indications fueling market growth. As the market is highly dominated by generics (which treat traditional conditions such as spasticity and spasm), label extensions will provide more opportunities for revenue generation. This is expected to propel the market growth substantially. Vendors are also increasingly focusing on developing drugs for the treatment of niche indications such as upper limb and lower limb spasticity. For instance, in April 2015, Allergan received expanded label indication for BOTOX for the treatment of adults with upper limb spasticity. Later in January 2016, Allergan received the US FDA approval for BOTOX for the treatment of lower limb spasticity in individuals to reduce the severity of increased muscle stiffness in toe and ankle muscles. Further, in August 2016, the Ipsen Group received the US FDA approval for its supplemental Biologics License Application for Dysport for the treatment of lower limb spasticity in pediatric individuals two years of age and older. The increase in label indications will expand the scope of muscle relaxants and drive the market growth.

Further, the report states that one challenge in market is side effects associated with use of muscle relaxants hamper adoption rates. Side effects associated with the use of muscle relaxants may hinder the adoption rates. For instance, carisoprodol and diazepam are classified by the US FDA as Schedule IV controlled substances due to their potential for addiction and abuse. Muscle relaxants are generally prescribed early for the treatment of back pain on a short-term basis. One reason for the short duration of the course is the potential for dependence, which may lead to drug abuse. In addition, the combination of muscle relaxants and antihistamines leads to an increase in emergency room visits for older adults. Muscle relaxants can also cause allergic reactions, which include swelling in the throat or extremities, hives, breathing difficulties, and chest tightness. Also, muscle relaxers are total body relaxants and induce sleepiness. In addition, improper usage of muscle relaxant can be harmful. Such issues may hamper their adoption and force customers to opt for alternative treatments for muscle spasticity or spasms.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Pfizer
  • Ipsen Group
  • Allergan
  • Novartis
  • Teva Pharmaceuticals
  • Acorda Therapeutics
  • Aldeyra Therapeutics
  • Canbex Therapeutics
  • Daewoong
  • Emcure Pharmaceuticals
  • Endo International
  • Fresenius Kabi
  • Galderma
  • INSYS Therapeutics
  • Johnson & Johnson
  • Lannett Company
  • Merz Pharma
  • Mylan
  • Par Pharmaceutical
  • PhytoTech Therapeutics
  • Revance Therapeutics
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll